所有图片(1)

主要文件

COA分析证书/COQ

341205

依托泊苷

Name: 依托泊苷
Brand: MM

≥95% (HPLC), solid, topoisomerase II inhibitor, Calbiochem

别名:

依托泊苷

登录查看公司和协议定价

所有图片(1)

About This Item

经验公式（希尔记法）:

C₂₉H₃₂O₁₃

CAS号:

33419-42-0

分子量:

588.56

MDL编号:

MFCD00869325

UNSPSC代码:

12352200

NACRES:

NA.77

推荐产品

Slide 1 of 10

1 of 10

Sigma-Aldrich

E1383

依托泊苷

Sigma-Aldrich

T7191

紫杉醇

Sigma-Aldrich

232120

顺铂

Sigma-Aldrich

D1515

阿霉素盐酸盐

E2600000

依托泊苷

Sigma-Aldrich

C2538

卡铂

Sigma-Aldrich

D2650

二甲基亚砜

Sigma-Aldrich

01885

Docetaxel

USP

1268808

依托泊苷

Sigma-Aldrich

APT800

细胞凋亡诱导剂套装

产品名称

依托泊苷, A cell-permeable derivative of podophyllotoxin that acts as a topoisomerase II inhibitor (IC₅₀ = 59.2 µM) has major activity against a number of tumors, including germ cell neoplasms, small cell lung cancer, and malignant lymphoma.

质量水平

100

方案

≥95% (HPLC)

表单

solid

制造商/商品名称

Calbiochem^®

储存条件

OK to freeze
protect from light

颜色

white

溶解性

DMSO: 25 mg/mL

运输

ambient

储存温度

10-30°C

SMILES字符串

O1[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O[C@H]3[C@@H]4[C@@H]([C@@H](c6c3cc7c(c6)OCO7)c5cc(c(c(c5)OC)O)OC)C(=O)OC4)CO[C@H]1C

InChI

1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1

InChI key

VJJPUSNTGOMMGY-MRVIYFEKSA-N

一般描述

一种细胞可渗透的拓扑异构酶II抑制剂（IC₅₀ = 59.2 µM）。一种鬼臼毒素衍生物（目录编号540040），对许多肿瘤（包括生殖细胞肿瘤、小细胞肺癌和恶性淋巴瘤）具有主要活性。在小鼠胸腺细胞和HL-60人白血病细胞中诱导凋亡。

一种细胞可渗透的鬼臼毒素衍生物，可用作拓扑异构酶II抑制剂（IC₅₀ = 59.2 µM），对许多肿瘤（包括生殖细胞肿瘤、小细胞肺癌和恶性淋巴瘤）具有主要活性。在小鼠胸腺细胞和HL-60人白血病细胞中诱导凋亡。

生化/生理作用

主要靶标
拓扑异构酶2

产物不与ATP竞争。

可逆：否

细胞可渗透性：是

靶标IC₅₀：59.2 µM，抑制拓扑异构酶II

警告

毒性：有害 & 致癌/致畸性（E）

重悬

复溶后，等分并冷冻保存（-20°C）。储备溶液在-20°C下可稳定保存至多3个月。

其他说明

De Lange, A.M., et al. 1995.J. Virol.69, 2082.
Kaufman, S.H., et al. 1993.Cancer Res.53, 3976.
Onishi, Y., et al. 1993.Biochim.Biophys.Acta1175, 147.
Terada, T., et al. 1993.J. Med. Chem. 36, 1689.
Wazniak, A.J., et al. 1991.J. Clin. Oncol.9, 70.
Einhorn, L.H., et al. 1988.J. Clin. Oncol.6, 451.
Issel, B.F.1982.Cancer Chemother.Pharmacol.7, 73.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

象形图

GHS08,GHS07

警示用语：

Danger

危险声明

H302,H350,H361d

预防措施声明

P202 - P264 - P270 - P280 - P301 + P312 - P308 + P313

危险分类

Acute Tox. 4 Oral - Carc. 1B - Repr. 2

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Ectopically Expressed Meiosis-Specific Cancer Testis Antigen HORMAD1 Promotes Genomic Instability in Squamous Cell Carcinomas.

Jennifer Gantchev et al.

Cells, 12(12) (2023-06-28)

Genomic instability is a prominent hallmark of cancer, however the mechanisms that drive and sustain this process remain elusive. Research demonstrates that numerous cancers with increased levels of genomic instability ectopically express meiosis-specific genes and undergo meiomitosis, the clash of

Sirtuin1 meditated modification of Notch1 intracellular domain regulates nucleolar localization and activation of distinct signaling cascades.

Neetu Saini et al.

Frontiers in cell and developmental biology, 10, 988816-988816 (2022-10-11)

Notch signaling is involved in cell fate decisions in the development and maintenance of tissue homeostasis. Spatial regulation of the Notch1 intracellular domain (NIC1), has been shown to underpin signaling outcomes mediated by this receptor. We recently reported a putative

Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study.

Carlo Cattrini et al.

Cancer treatment and research communications, 25, 100221-100221 (2020-10-23)

Etoposide phosphate (VP-16) is a topoisomerase 2 (TOP2) inhibitor that demonstrated activity in patients with metastatic castration-resistant prostate cancer (mCRPC). We investigated the sensitivity of prostate cancer (PCa) cells (LNCaP, 22Rv1, PC3, DU145, PDB and MDB) to VP-16 and the

Evidence of synergism among three genetic variants in a patient with LMNA-related lipodystrophy and amyotrophic lateral sclerosis leading to a remarkable nuclear phenotype.

Kathryn Volkening et al.

Molecular and cellular biochemistry, 476(7), 2633-2650 (2021-03-05)

Neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), can be clinically heterogeneous which may be explained by the co-inheritance of multiple genetic variants that modify the clinical course. In this study we examine variants in three genes in a family with

Transcriptome modulation following administration of luteolin to bleomycin-etoposide-cisplatin chemotherapy on rat LC540 tumor Leydig cells.

Ha Tuyen Nguyen et al.

Andrologia, 53(2), e13960-e13960 (2021-01-06)

Leydig cell tumours represent 1%-3% of all cases of testicular tumours in men. Such tumours respond poorly to radiation or chemotherapy, including bleomycin-etoposide-cisplatin (BEP) combinatorial therapy. In this study, we investigated an alternative approach involving luteolin to improve the efficacy

查看所有相关文献

主要文件

依托泊苷

≥95% (HPLC), solid, topoisomerase II inhibitor, Calbiochem

About This Item

推荐产品

属性

产品名称

质量水平

方案

表单

制造商/商品名称

储存条件

颜色

溶解性

运输

储存温度

SMILES字符串

InChI

InChI key

说明

一般描述

生化/生理作用

警告

重悬

其他说明

法律信息

安全信息

象形图

警示用语：

危险声明

预防措施声明

危险分类

储存分类代码

WGK

文件

分析证书(COA)

已有该产品？

同行评审论文

技术文章和实验方案

相关内容

技术服务